Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $22.0 million.

  • Lifecore Biomedical, Inc. \De\'s Accumulated Expenses fell 257.34% to $22.0 million in Q2 2025 from the same period last year, while for May 2025 it was $22.0 million, marking a year-over-year decrease of 257.34%. This contributed to the annual value of $22.0 million for FY2025, which is 257.34% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Accumulated Expenses amounted to $22.0 million in Q2 2025, which was down 257.34% from $19.7 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Accumulated Expenses registered a high of $22.5 million during Q2 2024, and its lowest value of $3.3 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $5.7 million (2022), whereas its average is $8.2 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 5364.05% in 2023, then surged by 44373.94% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Accumulated Expenses (Quarter) stood at $3.3 million in 2021, then rose by 26.04% to $4.1 million in 2022, then dropped by 18.27% to $3.4 million in 2023, then skyrocketed by 38.07% to $4.6 million in 2024, then surged by 374.15% to $22.0 million in 2025.
  • Its Accumulated Expenses was $22.0 million in Q2 2025, compared to $19.7 million in Q1 2025 and $4.6 million in Q4 2024.